Chronic Heart Failure Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug class (Anti-clotting, Antiplatelet medicines, Anticoagulant medicines, Angiotensin converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARB), Statins, Nitrates, Diuretics, If Channel Blocker, Vaccines); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and geography

Report Code: TIPRE00018099 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

A chronic progressive condition that affects the pumping power of heart muscles is chronic heart failure. While sometimes referred to as "heart failure," it refers explicitly to the process in which fluid builds up around the heart and causes it to pump inefficiently. Heart failure treatment normally attempts to control the symptoms for as long as possible and to delay the progression of the disease. Medication treatment plan may include different classes of drugs in the form of branded drugs and generic drugs.

MARKET DYNAMICS

Factors driving the growth of the chronic heart failure treatment market are the growing prevalence of cardiovascular diseases (CVD), coupled with increasing technological advanced products. However, the high cost of treatment is expected to hamper the growth of the market. Moreover, favorable reimbursement policies and rising geriatric population is anticipated to boost the market growth.

MARKET SCOPE

The "Chronic Heart Failure Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of chronic heart failure drugs market with detailed market segmentation by drug class and distribution channel. The chronic heart failure drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in chronic heart failure drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The chronic heart failure drugs market is segmented on the basis of drug class and distribution channel. On the basis of drug class, the market is categorized as anti-clotting, antiplatelet medicines, anticoagulant medicines, Angiotensin converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARB), statins, nitrates, statins, If Channel Blocker, and vaccines. Antiplatelet medicines categorized as Clopidogrel, Prasugrel, and Ticagrelor. On the basis of end-user, the market is categorized as hospitals pharmacies, retail pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the chronic heart failure drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The chronic heart failure drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting chronic heart failure drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the chronic heart failure drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the chronic heart failure drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from chronic heart failure drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for chronic heart failure drugs in the global market. Below mentioned is the list of few companies engaged in the chronic heart failure drugs market.

The report also includes the profiles of key players in chronic heart failure drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Pfizer
  •  GlaxoSmithKline plc
  •  Novartis International AG.
  •  Bristol-Myers Squibb Company
  •  Merck Sharp & Dohme
  •  AstraZeneca
  •  Berlin Heart GmbH
  •  Medtronic plc.
  •  ReliantHeart, Inc.
  •  St. Jude Medical Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Heart Failure Drugs Market - By Drug class
1.3.2 Chronic Heart Failure Drugs Market - By Distribution Channel
1.3.3 Chronic Heart Failure Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHRONIC HEART FAILURE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHRONIC HEART FAILURE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CHRONIC HEART FAILURE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC HEART FAILURE DRUGS - GLOBAL MARKET OVERVIEW
6.2. CHRONIC HEART FAILURE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHRONIC HEART FAILURE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ANTI-CLOTTING
7.3.1. Overview
7.3.2. Anti-clotting Market Forecast and Analysis
7.4. ANTIPLATELET MEDICINES
7.4.1. Overview
7.4.2. Antiplatelet medicines Market Forecast and Analysis
7.4.3. Clopidogrel Market
7.4.3.1. Overview
7.4.3.2. Clopidogrel Market Forecast and Analysis
7.4.4. Prasugrel Market
7.4.4.1. Overview
7.4.4.2. Prasugrel Market Forecast and Analysis
7.4.5. Ticagrelor Market
7.4.5.1. Overview
7.4.5.2. Ticagrelor Market Forecast and Analysis
7.5. ANTICOAGULANT MEDICINES
7.5.1. Overview
7.5.2. Anticoagulant medicines Market Forecast and Analysis
7.6. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
7.6.1. Overview
7.6.2. Angiotensin converting enzyme (ACE) inhibitors Market Forecast and Analysis
7.7. ANGIOTENSIN II RECEPTOR BLOCKERS (ARB)
7.7.1. Overview
7.7.2. Angiotensin II receptor blockers (ARB) Market Forecast and Analysis
7.8. STATINS
7.8.1. Overview
7.8.2. Statins Market Forecast and Analysis
7.9. NITRATES
7.9.1. Overview
7.9.2. Nitrates Market Forecast and Analysis
7.10. DIURETICS
7.10.1. Overview
7.10.2. Diuretics Market Forecast and Analysis
7.11. IF CHANNEL BLOCKER
7.11.1. Overview
7.11.2. If Channel Blocker Market Forecast and Analysis
7.12. VACCINES
7.12.1. Overview
7.12.2. Vaccines Market Forecast and Analysis
8. CHRONIC HEART FAILURE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS PHARMACIES
8.3.1. Overview
8.3.2. Hospitals Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. CHRONIC HEART FAILURE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Chronic Heart Failure Drugs Market Overview
9.1.2 North America Chronic Heart Failure Drugs Market Forecasts and Analysis
9.1.3 North America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Drug class
9.1.4 North America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Chronic Heart Failure Drugs Market
9.1.5.1.1 United States Chronic Heart Failure Drugs Market by Drug class
9.1.5.1.2 United States Chronic Heart Failure Drugs Market by Distribution Channel
9.1.5.2 Canada Chronic Heart Failure Drugs Market
9.1.5.2.1 Canada Chronic Heart Failure Drugs Market by Drug class
9.1.5.2.2 Canada Chronic Heart Failure Drugs Market by Distribution Channel
9.1.5.3 Mexico Chronic Heart Failure Drugs Market
9.1.5.3.1 Mexico Chronic Heart Failure Drugs Market by Drug class
9.1.5.3.2 Mexico Chronic Heart Failure Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Chronic Heart Failure Drugs Market Overview
9.2.2 Europe Chronic Heart Failure Drugs Market Forecasts and Analysis
9.2.3 Europe Chronic Heart Failure Drugs Market Forecasts and Analysis - By Drug class
9.2.4 Europe Chronic Heart Failure Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Chronic Heart Failure Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Chronic Heart Failure Drugs Market
9.2.5.1.1 Germany Chronic Heart Failure Drugs Market by Drug class
9.2.5.1.2 Germany Chronic Heart Failure Drugs Market by Distribution Channel
9.2.5.2 France Chronic Heart Failure Drugs Market
9.2.5.2.1 France Chronic Heart Failure Drugs Market by Drug class
9.2.5.2.2 France Chronic Heart Failure Drugs Market by Distribution Channel
9.2.5.3 Italy Chronic Heart Failure Drugs Market
9.2.5.3.1 Italy Chronic Heart Failure Drugs Market by Drug class
9.2.5.3.2 Italy Chronic Heart Failure Drugs Market by Distribution Channel
9.2.5.4 Spain Chronic Heart Failure Drugs Market
9.2.5.4.1 Spain Chronic Heart Failure Drugs Market by Drug class
9.2.5.4.2 Spain Chronic Heart Failure Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Chronic Heart Failure Drugs Market
9.2.5.5.1 United Kingdom Chronic Heart Failure Drugs Market by Drug class
9.2.5.5.2 United Kingdom Chronic Heart Failure Drugs Market by Distribution Channel
9.2.5.6 Rest of Europe Chronic Heart Failure Drugs Market
9.2.5.6.1 Rest of Europe Chronic Heart Failure Drugs Market by Drug class
9.2.5.6.2 Rest of Europe Chronic Heart Failure Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Chronic Heart Failure Drugs Market Overview
9.3.2 Asia-Pacific Chronic Heart Failure Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Chronic Heart Failure Drugs Market Forecasts and Analysis - By Drug class
9.3.4 Asia-Pacific Chronic Heart Failure Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Chronic Heart Failure Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Chronic Heart Failure Drugs Market
9.3.5.1.1 Australia Chronic Heart Failure Drugs Market by Drug class
9.3.5.1.2 Australia Chronic Heart Failure Drugs Market by Distribution Channel
9.3.5.2 China Chronic Heart Failure Drugs Market
9.3.5.2.1 China Chronic Heart Failure Drugs Market by Drug class
9.3.5.2.2 China Chronic Heart Failure Drugs Market by Distribution Channel
9.3.5.3 India Chronic Heart Failure Drugs Market
9.3.5.3.1 India Chronic Heart Failure Drugs Market by Drug class
9.3.5.3.2 India Chronic Heart Failure Drugs Market by Distribution Channel
9.3.5.4 Japan Chronic Heart Failure Drugs Market
9.3.5.4.1 Japan Chronic Heart Failure Drugs Market by Drug class
9.3.5.4.2 Japan Chronic Heart Failure Drugs Market by Distribution Channel
9.3.5.5 South Korea Chronic Heart Failure Drugs Market
9.3.5.5.1 South Korea Chronic Heart Failure Drugs Market by Drug class
9.3.5.5.2 South Korea Chronic Heart Failure Drugs Market by Distribution Channel
9.3.5.6 Rest of Asia-Pacific Chronic Heart Failure Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Chronic Heart Failure Drugs Market by Drug class
9.3.5.6.2 Rest of Asia-Pacific Chronic Heart Failure Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Chronic Heart Failure Drugs Market Overview
9.4.2 Middle East and Africa Chronic Heart Failure Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Chronic Heart Failure Drugs Market Forecasts and Analysis - By Drug class
9.4.4 Middle East and Africa Chronic Heart Failure Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Chronic Heart Failure Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Chronic Heart Failure Drugs Market
9.4.5.1.1 South Africa Chronic Heart Failure Drugs Market by Drug class
9.4.5.1.2 South Africa Chronic Heart Failure Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Chronic Heart Failure Drugs Market
9.4.5.2.1 Saudi Arabia Chronic Heart Failure Drugs Market by Drug class
9.4.5.2.2 Saudi Arabia Chronic Heart Failure Drugs Market by Distribution Channel
9.4.5.3 U.A.E Chronic Heart Failure Drugs Market
9.4.5.3.1 U.A.E Chronic Heart Failure Drugs Market by Drug class
9.4.5.3.2 U.A.E Chronic Heart Failure Drugs Market by Distribution Channel
9.4.5.4 Rest of Middle East and Africa Chronic Heart Failure Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Chronic Heart Failure Drugs Market by Drug class
9.4.5.4.2 Rest of Middle East and Africa Chronic Heart Failure Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Chronic Heart Failure Drugs Market Overview
9.5.2 South and Central America Chronic Heart Failure Drugs Market Forecasts and Analysis
9.5.3 South and Central America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Drug class
9.5.4 South and Central America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Chronic Heart Failure Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Chronic Heart Failure Drugs Market
9.5.5.1.1 Brazil Chronic Heart Failure Drugs Market by Drug class
9.5.5.1.2 Brazil Chronic Heart Failure Drugs Market by Distribution Channel
9.5.5.2 Argentina Chronic Heart Failure Drugs Market
9.5.5.2.1 Argentina Chronic Heart Failure Drugs Market by Drug class
9.5.5.2.2 Argentina Chronic Heart Failure Drugs Market by Distribution Channel
9.5.5.3 Rest of South and Central America Chronic Heart Failure Drugs Market
9.5.5.3.1 Rest of South and Central America Chronic Heart Failure Drugs Market by Drug class
9.5.5.3.2 Rest of South and Central America Chronic Heart Failure Drugs Market by Distribution Channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL CHRONIC HEART FAILURE DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CHRONIC HEART FAILURE DRUGS MARKET, KEY COMPANY PROFILES
12.1. PFIZER
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GLAXOSMITHKLINE PLC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS INTERNATIONAL AG.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BRISTOL-MYERS SQUIBB COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK SHARP AND DOHME
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ASTRAZENECA
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BERLIN HEART GMBH
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MEDTRONIC PLC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. RELIANTHEART, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ST. JUDE MEDICAL INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer
2. GlaxoSmithKline plc
3. Novartis International AG.
4. Bristol-Myers Squibb Company
5. Merck Sharp & Dohme
6. AstraZeneca
7. Berlin Heart GmbH
8. Medtronic plc.
9. ReliantHeart, Inc.
10. St. Jude Medical Inc.
TIPRE00018099
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking